Inactive Instrument

Mologen AG Stock

MGNK

DE000A2LQ900

Biotechnology & Medical Research

Mologen AG is a Germany-based company engaged in the biotechnology and medical research industry. The Company specializes in the research and development of drugs in the fields of oncology and infectious diseases. The Company develops medicines and vaccines on the basis of its MIDGE, dSLIM and EnanDIM platform technologies and through the use of its human, allogeneic tumor cell bank. Within the area of oncology, the Company develops Lefitolimod, which is intended to enable the patient's immune system to recognize the body's own cancer cells and fight them, MGN1601, which works like a therapeutic vaccination against cancer, as well as MGN1404, which is targeted at malignant melanoma. Within the area of infectious diseases, the Company develops deoxyribonucleic acid (DNA) vaccines against leishmaniasis and hepatitis B.

Employees

Sector

Biotechnology & Medical Research

More about the company

Stock Market
Stocks
MGNK Stock

As early as today, start finding the best investment opportunities!

14/08/19	Mologen AG Announces Updates on Phase III IMPALA Study; Provides Earnings Guidance for the Full Year 2019	CI
27/03/19	Mologen AG Announces Management Changes	CI
01/08/18	Mologen AG Announces Management Changes	CI
20/04/18	Mariola Soehngen Not to Renew Her Position as Member and Chief Executive Officer on the Board of Directors of Mologen AG Which Expires on 31 October 2018	CI
17/08/16	Mologen Reports Earnings Results for the Six Months of 2016; Provides Earnings Guidance for the Full Year of 2016	CI
12/05/16	Mologen AG Announces Progress in Clinical Studies; Announces Earnings Results for the First Quarter of 2016; Confirms Earnings Guidance for the Year 2016	CI
22/03/16	Mologen AG Reports Earnings Results for the Year 2015	CI
16/03/16	MOLOGEN AG Appoints Walter Miller as Member of the Executive Board and Chief Financial Officer with Effect from April 1, 2016	CI
14/03/16	Mologen AG Announces Extension of TEACH Study Based on Supportive First Study Results	CI
25/02/16	Mologen AG Supports Development Strategy of lefitolimod (MGN1703)	CI
19/01/16	MOLOGEN AG and the University of Texas MD Anderson Cancer Center Enter into Collaboration Agreement Relating to Phase I trial with MOLOGEN’s Immunomodulator Lefitolimod in Combination with the Immunotherapy Yervoy® in Patients with Advanced Solid Malignancies	CI
12/11/15	MOLOGEN AG Reaffirms Earnings Guidance Financial Year 2015	CI
21/09/15	Mologen AG(XTRA:MGN) dropped from S&P Global BMI Index	CI

Director	Title	Age	Since
Gabriel Peter Salgo BRD	Director/Board Member	-	-
Frank Pauly BRD	Director/Board Member	-	-
Wenhai Wang BRD	Director/Board Member	72	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MOLOGEN AG	+25.00%	+25.00%	-	-	64.22K
LONZA GROUP AG	-0.18%	+4.35%	+4.23%	+31.79%	47.56B
IQVIA HOLDINGS INC.	-0.83%	-0.36%	+43.66%	+34.77%	44.09B
BEONE MEDICINES AG	-0.84%	+4.86%	+10.92%	+91.52%	41.5B
REVOLUTION MEDICINES, INC.	-1.10%	-2.64%	+331.49%	+535.80%	40.88B
CELLTRION, INC.	-0.62%	+0.11%	+1.12%	+46.02%	29.67B
MEDPACE HOLDINGS, INC.	-2.07%	+0.12%	+24.39%	+154.30%	17.23B
EUROFINS SCIENTIFIC SE	-3.55%	+1.95%	+21.97%	+38.83%	15.06B
ASCENDIS PHARMA A/S	-6.08%	-9.92%	-	-	14.65B
TEMPUS AI, INC.	-0.78%	+9.46%	-8.96%	-	13.82B
Average	+0.99%	+0.69%	+53.60%	+133.29%	29.39B
Weighted average by Cap.	-1.09%	+0.96%	+67.22%	+141.34%

Mologen AG Stock

Stocks

MGNK

DE000A2LQ900

Biotechnology & Medical Research

Latest news: Mologen AG

Quotes and Performance

Managers and Directors: Mologen AG

Other Biotechnology & Medical Research

Company Profile